LUCD 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-12

• In July 2026, the Company secured its first positive coverage policy from a laboratory benefit manager that establishes genetic and molecular testing coverage policies for adoption by its client health plans. The policy considers EsoGuard medically necessary for patients who meet American College of…

• On April 24, 2026, the Company closed on the sale of 18,000,000 shares of its common stock at a price of $1.00 per share in a registered direct offering. The net proceeds of the offering, after deducting approximately $1.2 million of the underwriting discount and other expenses, was approximately $1…

• In the three months ended June 30, 2026, the cost of revenue was approximately $1.4 million as compared to $1.5 million for the corresponding period in the prior year. The $0.1 million decrease principally relates to a decrease in compensation costs.

• approximately $1.6 million increase primarily due to an increase in compensation, related personnel costs and stock-based compensation costs; and

• approximately $0.2 million increase in professional services and consulting costs.

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• Subsequent to March 31, 2026, on April 24, 2026, the Company closed on the sale of 18,000,000 shares of its common stock at a price of $1.00 per share in a registered direct offering. The net proceeds of the offering, after deducting approximately $1.2 million of the underwriting discount and other …

• In December 2025, the Company announced results from an 18-month real-world experience evaluating EsoGuard and EsoCheck in approximately 12,000 patients. The analysis demonstrated high technical success rates, rapid procedure times, and appropriate physician utilization in routine clinical practice,…

• In the three months ended March 31, 2026, the cost of revenue was relatively level at approximately $1.6 million, as compared to the corresponding period in the prior year.

• approximately $0.1 million increase in professional services and consulting costs; and

• approximately $0.1 million increase in the professional services based on current business activities received from PAVmed through the MSA agreement.

相对上期新增的文字 · 来源:10-Q · 2026-08-12

• During the fiscal quarter ended June 30, 2026, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• Subsequent to March 31, 2026, on May 13, 2026, the Company and a majority-in-interest of the holders of the 2024 Convertible Notes entered into a waiver agreement, pursuant to which they agreed that the holders would not declare that an event of default has occurred due to the Company's failure to o…

• During the fiscal quarter ended March 31, 2026, none of our directors or officers (as defined in Rule 16a-1 under the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (as those terms are defined in Item 408 of Regulation S-K).